HC Wainwright Reiterates “Buy” Rating for Zenas Biopharma (NASDAQ:ZBIO)

Zenas Biopharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 186.53% from the company’s current price.

Several other research firms also recently commented on ZBIO. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Zenas Biopharma in a report on Wednesday, March 12th. Wedbush reiterated an “outperform” rating and issued a $35.00 price objective on shares of Zenas Biopharma in a report on Thursday.

Zenas Biopharma Stock Up 7.5%

ZBIO opened at $10.47 on Friday. The company has a 50-day moving average of $8.92. Zenas Biopharma has a 1-year low of $5.83 and a 1-year high of $26.25. The firm has a market cap of $438.00 million and a PE ratio of -2.95.

Zenas Biopharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $5.00 million.

Hedge Funds Weigh In On Zenas Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. acquired a new position in shares of Zenas Biopharma in the first quarter valued at about $348,000. Nuveen LLC acquired a new position in shares of Zenas Biopharma in the first quarter valued at about $250,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Zenas Biopharma in the first quarter valued at about $49,000.

About Zenas Biopharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.